Champions Oncology (NASDAQ:CSBR) was downgraded by equities research analysts at ValuEngine from a “hold” rating to a “sell” rating in a research report issued to clients and investors on Wednesday.

Shares of Champions Oncology (NASDAQ:CSBR) traded down $0.14 during trading hours on Wednesday, hitting $3.54. The stock had a trading volume of 48,444 shares, compared to its average volume of 53,048. Champions Oncology has a 12 month low of $2.09 and a 12 month high of $4.79.

Champions Oncology (NASDAQ:CSBR) last issued its quarterly earnings data on Thursday, September 14th. The biotechnology company reported ($0.06) earnings per share (EPS) for the quarter. Champions Oncology had a negative return on equity of 338.01% and a negative net margin of 29.87%. The firm had revenue of $5.03 million for the quarter.

A hedge fund recently raised its stake in Champions Oncology stock. GRT Capital Partners L.L.C. raised its position in shares of Champions Oncology Inc (NASDAQ:CSBR) by 70.6% in the second quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 41,064 shares of the biotechnology company’s stock after acquiring an additional 17,000 shares during the period. GRT Capital Partners L.L.C. owned approximately 0.37% of Champions Oncology worth $106,000 at the end of the most recent quarter. Institutional investors and hedge funds own 38.04% of the company’s stock.

COPYRIGHT VIOLATION NOTICE: This piece of content was originally posted by American Banking News and is the sole property of of American Banking News. If you are reading this piece of content on another domain, it was stolen and republished in violation of United States & international trademark & copyright law. The legal version of this piece of content can be read at https://www.americanbankingnews.com/2017/12/06/valuengine-downgrades-champions-oncology-csbr-to-sell.html.

About Champions Oncology

Champions Oncology, Inc is engaged in the development and sale of technology solutions and products to personalize the development and use of oncology drugs. The Company has two business segments: Personalized Oncology Solutions (POS) and Translational Oncology Solutions (TOS). The POS segment provides physicians and patients information to help guide the development of personalized treatment plans.

To view ValuEngine’s full report, visit ValuEngine’s official website.

Receive News & Ratings for Champions Oncology Inc Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Champions Oncology Inc and related companies with MarketBeat.com's FREE daily email newsletter.